Gilead Science’s twice-yearly shot for treating HIV prevented new infections by 96% among patients in a late-stage trial, ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

In newly released data, lenacapavir, given via a twice-yearly injection, has shown remarkable effectiveness at eliminating ...

Gilead said Thursday that its twice-yearly antiviral reduced the risk of HIV infections by 96% compared to an expected rate ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Gilead has several patent applications in India on lenacapavir. Two of these patent applications, filed in 2020, seek patents ...

Drugmaker Gilead Science announced Thursday that its biannual injections to prevent against HIV had slashed the risk of ...

Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday. The data sets ...

The US-based Gilead Sciences’ long-acting injectable HIV drug lenacapavir is at the centre of a patent opposition case ...

J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...

On September 19, 2024, the Indian Patent Office will hear objections filed by Sankalp Rehabilitation Trust against Gilead's ...